Tazarotene Global Patent Coverage & Expiry Overview

Track protection status across key markets to assess launch feasibility.

Start your free 7-Day Trial! Book a demo to explore our global patent data.

It is formulated by 7 pharmaceutical companies such as MAYNE PHARMA, TARO, COSETTE and others. It is marketed under 5 brand names, including FABIOR, TAZAROTENE, DUOBRII and others. Available in 4 different strengths, such as 0.1%, 0.01%;0.045%, 0.045% and others, and administered through 4 routes including AEROSOL, FOAM;TOPICAL, CREAM;TOPICAL, LOTION;TOPICAL and others.

Strategic Dashboard

info

insightsStrategic Insights

Sourcing & Feasibility

check_circle API availability: autorenew Loading API feasibility...

groups Licensing: 7 potential partners

calendar_todayUS Launch window: autorenew Loading launch window...

timeline Key Patent Barrier & Expiry Timeline

autorenew Loading patent barriers...

factoryGeneric Manufacturer Snapshot

autorenew Loading manufacturers...

gavelRisk & Opportunity Summary

dangerous Risk: autorenew Loading risk analysis...
watch_later Watch: autorenew Loading watch analysis...
rocket_launch Opportunity: autorenew Loading opportunity analysis...
flag
gavel
calendar_today
calendar_today

Access Global Patent Data

Stay ahead with worldwide patent expiry and latest updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
Unlock Global Patents

Orange Book Drug Approval Timeline

FDA approval history for this ingredient

NDA (New Drug Application) ANDA (Generic Application)

Access Global Exclusivity and Patent Expiry Extensions

Stay ahead with worldwide patent expiry insights, exclusivity data, and latest updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
✓ Latest exclusivity data and extensions
Unlock Global Access

US Orange Book Patents Expiration Timeline

Key expiration dates for US patents covering this ingredient

View Global Patents Expiration Timeline

Stay ahead with worldwide patent expiry insights, market data, and research updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
Unlock Global Patent Timeline

Orange Book Drug Strengths

Latest drug strengths approved by FDA

Strength Route of Administration Companies Latest Approval Date

Orange Book Patents

Patents approved by the FDA for the ingredient

Patent Number Publication Date Legal Status Patent Expiry Date
{"application_id":"42794","ingredient":"TAZAROTENE","trade_name":"FABIOR","family_id":"b69d861d426b4640bf2a","publication_number":"US10688071B2","cleaned_patent_number":"10688071","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2030-02-24","publication_date":"2020-06-23","legal_status":"Granted"} US10688071B2 Formulation 23 Jun, 2020 Granted 24 Feb, 2030
{"application_id":"42793","ingredient":"TAZAROTENE","trade_name":"FABIOR","family_id":"b69d861d426b4640bf2a","publication_number":"US8808716B2","cleaned_patent_number":"8808716","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2030-02-24","publication_date":"2014-08-19","legal_status":"Granted"} US8808716B2 Formulation 19 Aug, 2014 Granted 24 Feb, 2030
{"application_id":"42775","ingredient":"TAZAROTENE","trade_name":"FABIOR","family_id":"b69d861d426b4640bf2a","publication_number":"US10568859B2","cleaned_patent_number":"10568859","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2030-02-24","publication_date":"2020-02-25","legal_status":"Patented case"} US10568859B2 Formulation 25 Feb, 2020 Patented case 24 Feb, 2030
{"application_id":"130699","ingredient":"HALOBETASOL PROPIONATE; TAZAROTENE","trade_name":"DUOBRII","family_id":"ca65ddf7d8bc40138e4c","publication_number":"US12076403B2","cleaned_patent_number":"12076403","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-11-02","publication_date":"2024-09-03","legal_status":"Granted"} US12076403B2 Formulation 03 Sep, 2024 Granted 02 Nov, 2031
{"application_id":"120713","ingredient":"HALOBETASOL PROPIONATE; TAZAROTENE","trade_name":"DUOBRII","family_id":"ca65ddf7d8bc40138e4c","publication_number":"US11839656B2","cleaned_patent_number":"11839656","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-11-02","publication_date":"2023-12-12","legal_status":"Granted"} US11839656B2 12 Dec, 2023 Granted 02 Nov, 2031
{"application_id":"63485","ingredient":"HALOBETASOL PROPIONATE; TAZAROTENE","trade_name":"DUOBRII","family_id":"ca65ddf7d8bc40138e4c","publication_number":"US8809307B2","cleaned_patent_number":"8809307","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-11-02","publication_date":"2014-08-19","legal_status":"Granted"} US8809307B2 Formulation 19 Aug, 2014 Granted 02 Nov, 2031
{"application_id":"63471","ingredient":"HALOBETASOL PROPIONATE; TAZAROTENE","trade_name":"DUOBRII","family_id":"ca65ddf7d8bc40138e4c","publication_number":"US10478502B2","cleaned_patent_number":"10478502","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-11-02","publication_date":"2019-11-19","legal_status":"Granted"} US10478502B2 Formulation 19 Nov, 2019 Granted 02 Nov, 2031
{"application_id":"63487","ingredient":"HALOBETASOL PROPIONATE; TAZAROTENE","trade_name":"DUOBRII","family_id":"ca65ddf7d8bc40138e4c","publication_number":"US11957753B2","cleaned_patent_number":"11957753","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-11-02","publication_date":"2024-04-16","legal_status":"Granted"} US11957753B2 Formulation 16 Apr, 2024 Granted 02 Nov, 2031
{"application_id":"63488","ingredient":"HALOBETASOL PROPIONATE; TAZAROTENE","trade_name":"DUOBRII","family_id":"ca65ddf7d8bc40138e4c","publication_number":"US11986527B2","cleaned_patent_number":"11986527","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-11-02","publication_date":"2024-05-21","legal_status":"Granted"} US11986527B2 21 May, 2024 Granted 02 Nov, 2031
{"application_id":"63465","ingredient":"TAZAROTENE","trade_name":"ARAZLO","family_id":"d558c5d165364dd98b7c","publication_number":"US11679116B2","cleaned_patent_number":"11679116","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-06-06","publication_date":"2023-06-20","legal_status":"Granted"} US11679116B2 Formulation 20 Jun, 2023 Granted 06 Jun, 2036
{"application_id":"63460","ingredient":"HALOBETASOL PROPIONATE; TAZAROTENE","trade_name":"DUOBRII","family_id":"badff805276d455188d6","publication_number":"US10426787B2","cleaned_patent_number":"10426787","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-06-06","publication_date":"2019-10-01","legal_status":"Granted"} US10426787B2 01 Oct, 2019 Granted 06 Jun, 2036
{"application_id":"115248","ingredient":"HALOBETASOL PROPIONATE; TAZAROTENE","trade_name":"DUOBRII","family_id":"d558c5d165364dd98b7c","publication_number":"US11648256B2","cleaned_patent_number":"11648256","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-06-06","publication_date":"2023-05-16","legal_status":"Granted"} US11648256B2 Formulation 16 May, 2023 Granted 06 Jun, 2036
{"application_id":"63464","ingredient":"HALOBETASOL PROPIONATE; TAZAROTENE","trade_name":"DUOBRII","family_id":"d558c5d165364dd98b7c","publication_number":"US11679115B2","cleaned_patent_number":"11679115","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-06-06","publication_date":"2023-06-20","legal_status":"Granted"} US11679115B2 Formulation 20 Jun, 2023 Granted 06 Jun, 2036
{"application_id":"63459","ingredient":"HALOBETASOL PROPIONATE; TAZAROTENE","trade_name":"DUOBRII","family_id":"badff805276d455188d6","publication_number":"US10251895B2","cleaned_patent_number":"10251895","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-06-06","publication_date":"2019-04-09","legal_status":"Granted"} US10251895B2 Formulation 09 Apr, 2019 Granted 06 Jun, 2036
{"application_id":"63466","ingredient":"TAZAROTENE","trade_name":"ARAZLO","family_id":"badff805276d455188d6","publication_number":"US20220233439A1","cleaned_patent_number":"12128137","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2038-05-11","publication_date":"2022-07-28","legal_status":"Pending"} US12128137B2 Formulation 28 Jul, 2022 Pending 11 May, 2038
{"application_id":"63437","ingredient":"TAZAROTENE","trade_name":"ARAZLO","family_id":"badff805276d455188d6","publication_number":"US11311482B2","cleaned_patent_number":"11311482","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2038-05-11","publication_date":"2022-04-26","legal_status":"Granted"} US11311482B2 26 Apr, 2022 Granted 11 May, 2038

Recent Clinical Trials

Latest clinical trials and research studies for this ingredient

NCT ID Title Status Phase Conditions Start Date Completion Date

API Suppliers/Manufacturer (Branded/Generic companies)

Manufacturing Locations

View Complete Supplier List

Unlock access to all suppliers of Tazarotene

✓ Access a comprehensive list of global suppliers
✓ Get information on each supplier
Unlock Suppliers

Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.

GreyB © 2025 Elixir. All rights reserved.